EA200400241A1 - Направленные к мишени мультимерные контрастные вещества, основанные на пептидах - Google Patents

Направленные к мишени мультимерные контрастные вещества, основанные на пептидах

Info

Publication number
EA200400241A1
EA200400241A1 EA200400241A EA200400241A EA200400241A1 EA 200400241 A1 EA200400241 A1 EA 200400241A1 EA 200400241 A EA200400241 A EA 200400241A EA 200400241 A EA200400241 A EA 200400241A EA 200400241 A1 EA200400241 A1 EA 200400241A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
target
directed
multimeral
substances based
Prior art date
Application number
EA200400241A
Other languages
English (en)
Other versions
EA006239B1 (ru
Inventor
Жаода Жанг
Питер Д. Караван
Томас Дж. Макмюрри
Эндрю Колодзидж
Шрикумар Наир
Джон С. Амедио
Стефан Дюма
Ксифанг Ванг
Вей-Чуан Сун
Александер Л. Ниворожкин
Штеффи К. Кернер
Original Assignee
Эпикс Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпикс Медикал, Инк. filed Critical Эпикс Медикал, Инк.
Publication of EA200400241A1 publication Critical patent/EA200400241A1/ru
Publication of EA006239B1 publication Critical patent/EA006239B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Описаны пептиды и основанные на пептидах направленные к мишени мультимерные контрастные вещества, а также способы получения и применения контрастных веществ.Отчет о международном поиске был опубликован 2003.05.22.
EA200400241A 2001-07-30 2002-07-30 Направленные к мишени мультимерные контрастные вещества, основанные на пептидах EA006239B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30872101P 2001-07-30 2001-07-30
PCT/US2002/024261 WO2003011115A2 (en) 2001-07-30 2002-07-30 Peptide-based multimeric targeted contrast agents

Publications (2)

Publication Number Publication Date
EA200400241A1 true EA200400241A1 (ru) 2004-06-24
EA006239B1 EA006239B1 (ru) 2005-10-27

Family

ID=23195121

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400241A EA006239B1 (ru) 2001-07-30 2002-07-30 Направленные к мишени мультимерные контрастные вещества, основанные на пептидах

Country Status (23)

Country Link
US (5) US20030180222A1 (ru)
EP (1) EP1420681B1 (ru)
JP (2) JP4298501B2 (ru)
KR (2) KR20040020074A (ru)
CN (1) CN1599577A (ru)
AR (1) AR036196A1 (ru)
AU (1) AU2002318931B2 (ru)
BR (1) BR0211623A (ru)
CA (1) CA2455638C (ru)
CO (1) CO5560528A2 (ru)
EA (1) EA006239B1 (ru)
EC (1) ECSP044996A (ru)
HU (1) HUP0402029A3 (ru)
IL (1) IL160001A0 (ru)
MX (1) MXPA04000967A (ru)
NO (1) NO20040402L (ru)
NZ (1) NZ531338A (ru)
PL (1) PL368807A1 (ru)
TW (2) TWI284539B (ru)
UA (2) UA84432C2 (ru)
WO (1) WO2003011115A2 (ru)
YU (1) YU9404A (ru)
ZA (1) ZA200401606B (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
US20060148683A1 (en) * 2001-10-16 2006-07-06 Mcmurry Thomas J Detection and treatment of intravascular lesions
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2006121889A2 (en) * 2005-05-06 2006-11-16 Epix Pharmaceuticals, Inc. Chemical exchange saturation transfer contrast agents
JP4559922B2 (ja) * 2005-06-21 2010-10-13 株式会社東芝 蛍光性錯体及びそれを用いた照明装置
WO2007009058A2 (en) 2005-07-13 2007-01-18 Georgia State University Research Foundation, Inc. Contrast agents and methods for preparing contrast agents
KR100703593B1 (ko) * 2005-08-08 2007-04-06 경북대학교 산학협력단 Ｄｔｐａ-비스（피콜린아미드）리간드，이를 포함하는가돌리늄 착물 및 이들의 제조 방법
CA2621763C (en) * 2005-09-09 2021-04-06 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1933884B1 (en) * 2005-10-11 2017-09-06 Huntington Medical Research Institutes Imaging agents and methods of use thereof
EP2221385A3 (en) 2005-10-28 2010-12-01 Life Technologies Corporation Deubiquination assays
FI20055653A (fi) 2005-12-08 2007-06-09 Wallac Oy Leimausreagenssi
WO2007073792A1 (de) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung von 4,4-diphenylcyclohexanol
US8034898B2 (en) * 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
US8481272B2 (en) * 2006-08-04 2013-07-09 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
CA2671431C (en) 2006-12-14 2019-03-26 Georgia State University Research Foundation, Inc. Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
CA2711426C (en) 2008-01-08 2018-05-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US20090236541A1 (en) * 2008-03-24 2009-09-24 General Electric Company System and Methods for Optical Imaging
EP3498307A1 (en) 2008-04-02 2019-06-19 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
CA2732973A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
EP2328922A4 (en) 2008-08-07 2013-01-02 Ipsen Pharma Sas ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE
EP2915538A3 (en) * 2008-08-07 2015-10-14 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
KR20130133103A (ko) * 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
US8864821B2 (en) * 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
WO2010121133A2 (en) * 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20120107248A1 (en) * 2009-07-08 2012-05-03 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
WO2011059609A2 (en) 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
EP2576502B1 (en) * 2010-06-01 2020-08-05 Cytiva BioProcess R&D AB Novel chelator and use thereof
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
US9011816B2 (en) * 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
US9849201B2 (en) * 2013-05-03 2017-12-26 Washington University Homing agents
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
US10610608B2 (en) 2013-08-01 2020-04-07 Rochester Institute Of Technology Modular imaging agents containing amino acids and peptides
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US10471162B2 (en) 2014-06-20 2019-11-12 The General Hospital Corporation Collagen targeted imaging probes
AU2016258123A1 (en) * 2015-05-06 2018-01-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target MC1R
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10301358B2 (en) 2015-06-29 2019-05-28 Collagen Medical, LLC Collagen imaging compositions
US10835623B2 (en) 2015-08-13 2020-11-17 The General Hospital Corporation Manganese-based chelate conjugates for molecular MR imaging
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN106946926A (zh) * 2017-02-27 2017-07-14 西北大学 一种具有多齿氨羧类二聚体螯合剂及其制备方法、应用和分离介质
CA3062553C (en) 2017-05-05 2024-02-06 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
AU2018261890A1 (en) 2017-05-05 2019-11-28 Centre For Probe Development And Commercialization IGF-1R monoclonal antibodies and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CA3120665A1 (en) 2018-11-23 2020-05-28 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
CN111233714B (zh) * 2020-03-18 2022-04-08 滨海吉尔多肽有限公司 一种maps多肽的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5001230A (en) 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9111199D0 (en) 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5641878A (en) 1991-05-15 1997-06-24 Diatron Corporation Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
CA2104860A1 (en) * 1991-03-08 1992-09-09 Thomas T. Andersen Endothelin antagonists
EP0630265B1 (en) 1992-03-13 2003-04-16 Diatide, Inc. TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION
US5637759A (en) * 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
US5705143A (en) * 1994-01-12 1998-01-06 Amersham International Plc Biological targeting agents
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
TW319763B (ru) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE19539409C2 (de) 1995-10-11 1999-02-18 Diagnostikforschung Inst Kontrastmittel für die Nahinfrarot-Diagnostik
DK0857216T3 (en) 1995-10-17 2014-12-15 Ab Enzymes Oy Cellulases, GENES ENCODING THEM AND USES THEREOF
EP1325932B9 (en) 1997-04-07 2006-07-19 Genentech, Inc. Anti-vegf antibodies
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
AU768859B2 (en) * 1999-07-29 2004-01-08 Dyax Corp. Binding moieties for fibrin
CN1382062A (zh) 1999-07-29 2002-11-27 埃匹克斯医学股份有限公司 通过多位点结合的寻靶多体造影剂
AU780730B2 (en) 1999-10-01 2005-04-14 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
WO2001030398A2 (en) 1999-10-22 2001-05-03 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
WO2001052906A2 (en) * 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide

Also Published As

Publication number Publication date
US7927581B2 (en) 2011-04-19
AR036196A1 (es) 2004-08-18
KR20040020074A (ko) 2004-03-06
IL160001A0 (en) 2004-06-20
TWI284539B (en) 2007-08-01
UA81226C2 (en) 2007-12-25
NZ531338A (en) 2005-08-26
AU2002318931B2 (en) 2008-01-17
TWI240632B (en) 2005-10-01
JP2005314438A (ja) 2005-11-10
WO2003011115A2 (en) 2003-02-13
JP2004536875A (ja) 2004-12-09
CA2455638C (en) 2013-01-22
CA2455638A1 (en) 2003-02-13
HUP0402029A2 (hu) 2005-01-28
ZA200401606B (en) 2005-05-03
YU9404A (sh) 2006-08-17
EA006239B1 (ru) 2005-10-27
EP1420681A2 (en) 2004-05-26
EP1420681A4 (en) 2009-08-05
CN1599577A (zh) 2005-03-23
PL368807A1 (en) 2005-04-04
TW200512006A (en) 2005-04-01
US20050074411A1 (en) 2005-04-07
US20030180222A1 (en) 2003-09-25
KR20080100856A (ko) 2008-11-19
ECSP044996A (es) 2004-06-28
US20030216320A1 (en) 2003-11-20
US7238341B2 (en) 2007-07-03
MXPA04000967A (es) 2005-02-17
BR0211623A (pt) 2004-07-13
NO20040402L (no) 2004-03-25
US20060039861A1 (en) 2006-02-23
UA84432C2 (ru) 2008-10-27
JP4298501B2 (ja) 2009-07-22
CO5560528A2 (es) 2005-09-30
US20070185311A1 (en) 2007-08-09
HUP0402029A3 (en) 2010-01-28
WO2003011115A3 (en) 2003-05-22
EP1420681B1 (en) 2013-12-25
US6991775B2 (en) 2006-01-31

Similar Documents

Publication Publication Date Title
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
EA199800946A1 (ru) Концентрированный препарат антител
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
EA200000310A1 (ru) April - новый белок, воздействующий на рост
EA200100053A1 (ru) Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат
DE60144145D1 (de) Subtilisin-variante
ATE399177T1 (de) Derivate therapeutischer peptide
EA200100012A1 (ru) Мостиковые инденопирролокарбазолы
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
EA199901013A1 (ru) Гели пролонгированного действия
EA200501250A1 (ru) Композиция, содержащая смесь активных начал, и способ ее получения
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
EA199800844A1 (ru) Способ получения r-альфа-пропил-пиперониламина и его аналогов, промежуточные продукты, используемые в этом способе
IL145689A0 (en) Methods
EA200501046A1 (ru) Эсциталопрамгидробромид и способ его получения
EA199900235A1 (ru) Аморфные бензотиофены, способы получения и способы применения
DE60039049D1 (de) Erhöhte expression von proteinen mittels gfp
ATE356207T1 (de) Humanes btrcp protein
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
EA200200798A1 (ru) Кальцилитические соединения

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU